Docstoc

NCI Cancer Bulletin

Document Sample
NCI Cancer Bulletin Powered By Docstoc
					                                    NCI Cancer Bulletin                               Eliminating the Suffering and Death Due to Cancer



                                                             NCI Launches Nanotechnology Alliance
September 14, 2004
Volume 1 | Number 35


In this issue:                                               Two panel discussions held yesterday        problem of great devastation that
NCI Launches
Nanotechnology Alliance...1                                  at the National Institutes of Health        requires new hope.”
                                                             (NIH)—one for science reporters and         Representatives from cancer centers,
Director’s Update...1
   Realizing the Promise of                                  one for researchers—marked the launch       industry, and federal agencies at-
    Nanotechnology                                           of the National Cancer Institute (NCI)      tended the discussion in person and
Cancer Research Highlights...3                               Alliance for Nanotechnology in Cancer,      via teleconference and webcast.
   Differences in Long-Term                                   a $144.3 million, 5-year initiative that    Dr. Anna Barker, deputy director of
    Outcomes After Prostate                                  brings together the physical, biological,
    Cancer Treatments                                                                                    NCI’s Advanced Technologies and
                                                             and medical science communities for a       Strategic Partnerships, gave a brief
   Chromosome Regions Linked
    to Prostate Cancer                                       common goal: directing nanotechnology       (continued on page 2)
   CDKN2A Mutation May                                       for the benefit of cancer patients.
    Increase Risk of Pancreatic
    Cancer                                                   “Today we have the opportunity to             More information on the NCI
   New Therapy Tested for Meta-                              renew our commitment to the con-              Alliance for Nanotechnology
    static Breast Cancer Tumors                              quest of cancer,” said NCI Director           in Cancer and the Cancer
   Two Studies Implicate Rho and                             Dr. Andrew C. von Eschenbach.                 Nanotechnology Plan is available
    TrkB Genes in Metastasis
                                                             “We’re talking about an emerging              at http://nano.cancer.gov.
Funding Opportunities...4                                    field of great promise, and an old
Community Update...5
   Consumer Group Names
    New Members, Shifts Focus
Featured Clinical Trial...6                                  Realizing the Promise of Nanotechnology
                                    D ire ctor ’s Up d ate




   Study of Individuals and
    Families at High Risk for
    Melanoma                                                 Yesterday marked the official launch of       enabling clinicians to rapidly deter-
Notes...7                                                    the NCI Alliance for Nanotechnology         mine whether a treatment is working.
   Medicare Cancer Drug Benefit                               in Cancer, an initiative that I believe     Other work has shown the ability of
   Enrollment Period Expanded                                could be a transformational event that      targeted nanodevices to elude bio-
   Scientific Presentations,                                  moves the science of nanotechnology         logical blockades and transport high
    Survivor Reflection Papers
    Available Online
                                                             from a promising medical application        concentrations of multiple therapeu-
   President’s Cancer Panel Holds                            to a central component in a new era in      tics directly to cancer cells and the
    First of Four Meetings                                   the diagnosis, monitoring, prevention,      tissues in their immediate microen-
   Evans to Speak on Obesity                                 and treatment of cancer. When com-          vironment. In this way, not only are
    and Cancer                                               bined with the strides we have made         healthy cells spared, but malignant
Featured Meetings...8                                        in understanding cancer at the genetic,     cells and their allies in metastasis are
                                                             cellular, and molecular levels, nano-       eliminated. Nanotechnology also is
                                                             technology may provide a whole new          making existing technologies more
                                                             category of interventions that were         effective. In research presented at the
                                                             not envisioned even 5 to 10 years ago.      American Association for Cancer
A Publication of the                                         The potential uses of nanodevices are       Research annual meeting in March,
National Cancer Institute
                                                             staggering. Early research indicates,       for example, NCI researchers pre-
U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES                                           for instance, that nanosystems may          sented results from work in mice that
National Institutes of Health
                                                             allow for real-time assessments of          showed that a nanoscale contrast
                                                                                                         (continued on page 2)
http://cancer.gov                                            therapeutic and surgical procedures,
                                                                                                                             1 NCI Cancer Bulletin
(Nanotechnology continued from page 1)         play in assessing the performance of        individual projects using the R01 grant
overview of its components: funding            nanotechnology devices. Continuing          mechanism. Development of multidis-
research through three to five Centers          the discussion of nanotechnology            ciplinary teams will train researchers
of Cancer Nanotechnology Excellence,           safety and industrialization was Dr.        to apply nanotechnology expertise to
as well as individual investigators;           Vicki Colvin, associate professor of        cancer research and clinical oncology
fostering multidisciplinary team as-           chemistry and director of the Center        questions. Finally, we are establishing a
sembly via interdisciplinary training;         for Biological and Environmental            program that will make nanomaterials
and establishing a Nanotechnology              Nanotechnology at Rice. Dr. Gregory         and nanoscale devices available to
Characterization Laboratory at NCI’s           Downing, director of the NCI Office of        researchers, thus hastening applications
Frederick, Md., facility.                      Technology and Industrial Relations,        with the greatest promise into clinical use.
Dr. Richard Smalley, Nobel laureate,           provided details about the Alliance,        We are pursuing nanotechnology
nanotechnology pioneer, and professor          including background on how its             because of its inherent promise to
at Rice University, described nanotech-        blueprint—the Cancer Nanotechnology         speed progress toward eliminating
nology in the context of patients. “The        Plan—was developed.                         the suffering and death due to can-
best answer to cancer is never to get          The final panel member, Phillip Bond,        cer. As such, we have built into this
it in the first place. But the next best        under secretary of commerce for             initiative processes for reducing or
answer is to find it when it first hap-          technology at the U.S. Department of        eliminating barriers to success. For
pens and be able to monitor month by           Commerce, said, “I look forward to          example, we are collaborating with
month and see if treatment is making           meeting the bold challenge that Dr.         the FDA to ensure that new nanotech-
it better or worse,” he said. “If we can       von Eschenbach has spelled out here         based interventions are developed in
do that, we can eliminate this disease…        to defeat cancer by 2015.” He discussed     such a way that they can move swiftly
for the vast majority of humankind.”           how the National Institute of Standards     through the regulatory process.
Dr. Mauro Ferrari, special expert              and Technology (NIST) will work with        NCI has also entered into a memo-
to NCI on nanotechnology and a                 the Alliance through shared facilities      randum of understanding with NIST,
professor at Ohio State University,            and collaboration on research, training,    a world leader in nanotechnology,
described nanoscale devices that are           and program planning. “We salute NCI        that will provide the framework for
already being used in clinical appli-          for their work here,” he said, “and we      training, the formation of interdisci-
cations. “If nanotechnology is fully           look forward to the many benefits for        plinary research teams, and the rapid
integrated in the cancer enterprise, it        the next generation.” d                     transfer of new interventions from
can help deliver therapy, reduce side                                                      the research lab to the marketplace.
effects, and transform what is, in too          (Director’s Update continued from page 1)
                                               agent vastly enhanced the ability of        This effort is not a blind leap into
many cases, an acute disease into a                                                        unfamiliar territory. On the contrary,
manageable disease,” he said.                  MRI to detect breast cancer lymph
                                               node metastases.                            NCI is already a leader in conducting
Dr. Samuel Wickline, professor at                                                          and funding nanotechnology research.
Washington University, relayed his             The NCI Alliance for Nanotechnology         In addition, NCI was the lead NIH
experience in nanotechnology research,         in Cancer was formed to fulfill this         institute in a review of nanotechnology
citing differences in the “languages”           technology’s promise. Through this          under the Government Performance
used by physical, biological, and clinical     initiative, NCI will support three to       and Results Act. This initiative is the
scientists, as well as in regulatory affairs,   five centers of excellence in cancer         next logical step for NCI to fulfill the
as barriers that will be overcome by the       nanotechnology that will operate as         promise of nanotechnology and the
NCI Nanotech Alliance. Dr. Wickline            a consortium. The establishment of          investment we have already made in
is an NCI investigator establishing            these centers will be a competitive         it. Beyond that, however, this effort is
new nanoparticle-based imaging and             process during which we will place          just one part of our broader investment
anti-angiogenesis therapies that are in        a premium on the development of             in technologies—an investment that
clinical development.                          crossdisciplinary teams that partner        I believe will help improve and save
                                               with existing NCI-supported efforts          many lives, and not just from cancer,
Dr. Janet Woodcock, acting deputy              and the private sector.
commissioner for operations of the                                                         but from many diseases. d
Food and Drug Administration (FDA),            In addition to the centers of excellence,   Dr. Andrew C. von Eschenbach
outlined the role that her agency will         the nanotechnology platforms for can-       Director, National Cancer Institute
                                               cer research will enable development of
2 NCI Cancer Bulletin
                                                                                    “The large number of…families in our
                                                                                    study will make it possible to test for
               Cancer Research                                                      gene-gene interactions in future link-
                                                                                    age analyses,” the authors wrote. They

               Highlights                                                           added that “results of this large ge-
                                                                                    nome-wide scan for prostate cancer
                                                                                    susceptibility genes provide a basis
                                                                                    for renewed interest, excitement, and
Differences in Long-Term                   surgery with EBRT, the authors iden-
                                                                                    confidence in genetic linkage studies
Outcomes after Prostate                   tified the need for additional prospec-
                                                                                    of prostate cancer.”
Cancer Treatments                         tive research using population-based
Five years after treatment with radical   samples comparing complications           CDKN2A Mutation
prostatectomy or external beam ra-        from all available treatments, includ-    May Increase Risk of
diotherapy (EBRT) for localized pros-     ing radioactive seed implants and         Pancreatic Cancer
tate cancer, men continue to live with    hormonal therapy.                         CDKN2A is the major known mela-
the treatment’s effects on their quality   Chromosome Regions                        noma susceptibility gene, but a recent
of life, according to NCI scientists.     Linked to Prostate Cancer                 study that looked at prospective risk
In the September 15 Journal of the        An international team of researchers      of cancers other than melanoma
National Cancer Institute, Dr. Arnold     has identified chromosome regions          found that CDKN2A mutations could
L. Potosky and colleagues from NCI’s      that may be related to prostate cancer    also increase the risk of pancreatic
SEER Program published a study on         susceptibility, according to a paper in   cancer. The study, which appeared
quality of life outcomes after prostate   the August 18 Journal of the National     in the June 2004 Journal of Medical
cancer treatment.                         Cancer Institute. Using genome-wide       Genetics, was conducted by Dr. Alisa
Using survey data collected from          scanning techniques, the NCI-funded       Goldstein and colleagues in the
more than 1,100 men enrolled in the       study analyzed blood samples from         Division of Cancer Epidemiology
Prostate Cancer Outcomes Study            families with a high incidence of         and Genetics at NCI. While most
(PCOS), begun in 1994, research-          prostate cancer.                          previous studies used family muta-
ers analyzed long-term side effects                                                  tion status, this study used individual
                                          Previous studies have shown that          mutation data in estimating risk.
for men treated either with radical       some genes may increase suscepti-
prostatectomy or EBRT. They found         bility for prostate cancer, but were      The authors determined the status of
that at 5 years after baseline diagno-    unable to pinpoint the exact genes or     the CDKN2A gene in 253 individual
sis, overall sexual function, includ-     chromosome regions responsible due        family members from 15 families
ing libido, frequency, and potency,       to small sample sizes, heterogene-        known to carry hereditary CDKN2A
declined to a similar level in both       ity, environment-induced cases, and       mutations; 117 individuals tested
treatment groups. Erectile dysfunc-       other factors.                            positive for the mutation (carriers)
tion and incontinence were reported                                                 and 136 tested negative for the muta-
more frequently in the radical prosta-    To address these issues, Dr. Jeffrey       tion (noncarriers). The researchers
tectomy group at 5 years, while bowel     Trent of the Translational Genomics       then compared the cancer incidence
urgency and hemorrhoids were cited        Research Institute and colleagues         between the two groups, using the
more often in the EBRT group.             conducted a genetic mapping study of      expected incidence rates for the gen-
                                          426 families from 4 existing hereditary   eral population as a baseline.
The authors note that “because there      prostate cancer studies. Dr. Trent’s
is continuing uncertainty about the       team primarily used nonparametric         Twelve mutation carriers developed a
superiority of any single treatment       multipoint linkage analysis, grouping     cancer other than melanoma during
strategy for clinically localized pros-   families with similar clinical and de-    the study period, compared with only
tate cancers…patient preferences for      mographic backgrounds to limit het-       two cancers among the noncarriers.
outcomes among competing treat-           erogeneity. They found one chromo-        Pancreatic cancer (four cases among
ment strategies may be an important       some region, 17q22, that was strongly     carriers) was the most predominant,
factor that drives treatment deci-        linked to prostate cancer. Through        and since the expected number
sions.” Although this study compared      stratified analysis, other regions were    within the general population is only
                                                                                    (continued on page 4)
                                          shown to possibly be linked.
                                                                                                        3 NCI Cancer Bulletin
(Research Highlights continued from page 3)   were enrolled in the study. The pa-
0.1 cases, these data suggest that the        tients underwent a reduced-intensity
risk of developing pancreatic cancer
is significantly increased in individu-
                                              transplant conditioning regimen be-
                                              fore the allogeneic HSCT treatment.
                                                                                         Funding
als who carry the CDKN2A muta-
tion. “However,” said the authors,
                                              Overall, six partial responses and four
                                              minor responses were observed after        Opportunities
“we cannot yet identify any specific           donor lymphocytes were given after
genotypes that predispose individuals         the transplant. For all 16 participants,   Quick-Trials for Novel Cancer
to pancreatic cancer.”                        the median overall survival time was       Therapies: Exploratory Grants
The authors cautioned that the                10.3 months.                               PAR-04-155
sample size was limited, so studies           While these results suggest that           Application Receipt Dates: Dec. 9, 2004;
                                                                                         Apr. 9, Aug. 9, Dec. 9, 2005; Apr. 9, Aug. 9,
with more individuals and a broader           metastatic breast cancer may be            Dec. 9, 2006; Apr. 9, Aug. 9, Dec. 9, 2007
spectrum of CDKN2A mutations are              treated using allogeneic HSCT, it is
required. Also, while nonmelanoma                                                        This PA replaces PAR-03-005.
                                              not an ideal treatment option in its
cancers were the focus of this study,         current form. The authors caution          This Program Announcement (PA) is
there were 49 cases of melanoma               that, “The observations of late tumor      intended to provide investigators with
and 14 melanoma deaths among                  regressions in this trial suggest that     rapid access to support for pilot, phase
the carriers during the study period.         immune-mediated responses against          I, and phase II cancer clinical trials as
“Melanoma remains the major con-              breast cancer are possible. The clini-     well as support for patient monitor-
tributor to morbidity and mortality in        cal question that remains is how to        ing and laboratory studies linked to a
these subjects,” noted the authors.           optimally and safely exploit the re-       cancer clinical trial. The focus of this
                                              sponses seen with allogeneic cellular      QUICK-TRIAL PA is on translational
New Therapy Tested
                                              therapy for metastatic breast cancer       research in new agent development to
for Metastatic Breast
                                              in the context of currently available      ensure the timely exploitation of new
Cancer Tumors
                                              treatments.”                               cancer therapeutic approaches includ-
Scientists from NCI’s Center for                                                         ing the development of new cancer
Cancer Research have investigated             Two Studies Implicate Rho                  prevention agents.
an alternative treatment for meta-            and TrkB Genes in Metastasis
static breast cancer patients. This                                                      This PA will use the NIH exploratory/
                                              One of the most insidious traits of
therapy—allogeneic hematopoietic                                                         development (R21) award mechanism.
                                              cancer cells is their ability to metas-
stem-cell transplantation (HSCT)—                                                        For more information see http://cri.
                                              tasize, or break away from, a primary
has been used to treat other blood                                                       nci.nih.gov/4abst.cfm?initiativeparfa_
                                              tumor and spread through the entire
cancers such as leukemia, but has                                                        id=2220. Inquiries: Dr. Roy Wu,
                                              body. A pair of recent studies now
been viewed with caution because                                                         wur@ctep.nci.nih.gov
                                              shows some of the mechanisms
of significant morbidity and mortal-           underlying metastasis—demonstrat-          Bioengineering Approaches to Energy
ity rates. However, recent advances           ing how cancer cells can detach from       Balance and Obesity (SBIR/STTR)
in reduced intensity transplant               their moorings and then survive            PA-04-156
conditioning regimens have been                                                          Application Receipt Dates: Dec. 1, 2004;
                                              when removed from the host tissue.
                                                                                         Apr. 1, Aug. 1, Dec. 1, 2005; Apr. 1, Aug. 1,
associated with decreased toxicity                                                       Dec. 1, 2006; Apr. 1, Aug. 1, 2007
                                              Most attached cells die when they
and raise the possibility of using al-
                                              become dislodged from their matrix,        The purpose of this PA is to solicit
logeneic HSCT as a treatment option.
                                              a process known as anoikis. Many           applications to develop and validate
In a study reported in the August 16
                                              cancer cells can survive, however,         new and innovative bioengineering
online Journal of Clinical Oncology,
                                              which allows them to invade foreign        technology to address clinical prob-
researchers investigated whether
                                              tissues. As reported in the August         lems related to energy balance, intake,
allogeneic HSCT could serve as a
                                              26 Nature, Dr. Daniel S. Peeper and        and expenditure. Novel sensors, de-
treatment for patients with metastatic
                                              colleagues at the Netherlands Cancer       vices, imaging, and other approaches
breast cancer.
                                              Institute found a gene—TrkB—that           are expected to be developed and
Between May 2000 and April 2003,              renders cells anoikis-resistant. The       evaluated by collaborating engineers,
16 metastatic breast cancer patients          main role of this gene is to promote       physical scientists, and scientists
                                              (continued on page 6)                      (continued on page 6)

4 NCI Cancer Bulletin
                                                                                     • Bobbie de Córdova-Hanks,
                                                                                       Bosom Buddies/Women’s Center
               Community Update                                                        of Jacksonville, Fla.
                                                                                     • Dr. Beverly Laird, American Cancer
                                                                                       Society/Susan G. Komen Breast
                                                                                       Cancer Foundation
                                                                                     • Dr. Sylvia M. Ramos,* People Living
                                                                                       Through Cancer/Intercultural Cancer
Consumer Group Names                      ovarian, breast, and prostate cancers.
                                                                                       Council
New Members, Shifts Focus                 Representatives from survivor and
                                                                                     • Eric Rosenthal, medical journalist/
NCI Director Dr. Andrew C. von            community groups and underserved
                                                                                       EvocaTalk® Reports
Eschenbach has reappointed 3              populations also serve as members.
                                                                                     • Mary Jackson Scroggins,* Ovarian
members and intends to appoint 12         “DCLG has historically been a wonder-        Cancer National Alliance
new members to the NCI Director’s         ful group of passionate people and this
                                                                                     • Sue Sumpter,* Leukemia and Lympho-
Consumer Liaison Group (DCLG) for         new group is the most diverse group of       ma Society/Candlelighters Childhood
2-, 3-, and 4-year terms. DCLG is a key   cancer advocates that we have ever had,      Cancer Foundation
group that brings together the cancer     representing all facets of people with
                                                                                     • Dr. Marisa C. Weiss, breastcancer.org
advocacy community and NCI. The           cancer,” Mr. Ulman adds.
                                                                                     • Celeste Whitewolf, Native People’s
group is shifting its focus to enhance    Dr. von Eschenbach said that he              Circle of Hope
communication between NCI and             expects incoming DCLG members              • Col. (Ret.) James E. Williams, Jr.,
patient-oriented constituent groups.      to build on the solid work of prior          U.S. Army, Pennsylvania Prostate
Begun in 1997, DCLG—a federally char-     DCLGs and open even more avenues             Cancer Coalition
tered committee—was the first all-con-     of contact between NCI and the            * APPOINTMENT PENDING
sumer advisory board at NIH. DCLG’s       cancer community. By promoting a
15 members advise and recommend a         productive exchange of information        For more information on DCLG,
wide variety of issues, programs, and     between the institute and its constitu-   go to http://deainfo.nci.nih.gov/
research priorities to the NCI director   ents, DCLG efforts will also enhance       ADVISORY/dclg/dclg.htm. d
from the perspective of people whose      other NCI initiatives as the institute
lives are affected by cancer.              continues to reach out to the public
                                          and make progress in the fight against
                                                                                     CCR Grand Rounds
To further its goal of broadening
communication, DCLG recently de-          cancer, he noted.                          September 21: Dr. David Paul
cided to focus on enhancing creative,     The new DCLG’s first meeting is             Carbone, Director, Lung Cancer
effective dialogue with the cancer         taking place September 13-15 in            SPORE, and Director, Experi-
advocacy community. It also will          Bethesda, Md. In addition to Mr.           mental Therapeutics Program,
increase its efforts in health disparity   Ulman, the incoming members, some          Vanderbilt-Ingram Cancer Center,
and cancer survivorship.                  of whose appointments are pending          will present “Molecular Signatures
                                          confirmation, are:                          of Lung Cancer.”
New DCLG Chairman Douglas
                                                                                     October 5: Dr. Judah Folkman,
Ulman, director of survivorship at         • Margaret L. Anthony, South Carolina
                                                                                     Andrus Professor of Pediatric
the Lance Armstrong Foundation               Chapter, Yul Brynner Head and Neck
                                             Foundation/Hollings Cancer Center/      Surgery and Professor of Cell
and returning DCLG member, says,
                                             Medical University of South Carolina    Biology, Harvard Medical School,
“We want to bridge the gap between
                                                                                     and Director, Vascular Biology
the cancer advocacy community and          • Vernal H. Branch, Virginia Breast
                                             Cancer Foundation/National Breast       Program, Children’s Hospital
NCI…so people understand how
                                             Cancer Coalition                        Boston, will present “Can the
they can go about speaking with the
                                                                                     Angiogenic Switch be Prevented
institute and effecting change.”            • William P. Bro,* Kidney Cancer
                                             Association                             in Human Cancer?”
DCLG members represent a broad
                                           • Lourie Campos,* Community Health        CCR Grand Rounds are held 8:30
spectrum of disease sites. Diseases
                                             Partnership                             to 9:30 a.m. at the NIH campus
currently represented include leu-
                                           • Nancy Davenport-Ennis,* Patient         in Bethesda, Md., in the Clinical
kemia and lymphoma; and kidney,
                                             Advocate Foundation                     Center’s Lipsett Auditorium. d

                                                                                                       5 NCI Cancer Bulletin
(Research Highlights continued from page 4)
the growth and survival of neural cells.
When expressed, TrkB can activate
a series of enzymes, including the
                                                                Featured Clinical Trial
PI3 kinases that prevent a cell from
destroying itself through apoptosis.
While Dr. Peeper’s findings help
explain how detached cancer cells               Study of Individuals and                    susceptibility genes and to look at
can survive, a study in the August 24           Families at High Risk for                   susceptibility to the disease resulting
Proceedings of the National Academy             Melanoma                                    from alterations in the genes already
of Sciences explains how some cancer                                                        identified.
                                                Name of the Trial
cells can break off from their host
                                                Study of Clinical, Laboratory, and          “We know that similar mutations in
tumors in the first place. Dr. Edward
                                                Epidemiologic Characteristics of            the major susceptibility genes confer
Bonder and colleagues at Rutgers
                                                Individuals and Families at High Risk       different risks in varying geographic
University found that overexpression
                                                for Melanoma (NCI-02-C-0211).               locations. Part of our task now is to
of the Rho gene can lead to improper
                                                See the protocol summary at http://         evaluate the contribution of both
orientation of the mitotic spindle
                                                cancer.gov/clinicaltrials/                                 genetic predisposition
during cell division. As a result, some
                                                NCI-02-C-0211.                                             and environmental ex-
of the newly formed daughter cells
                                                Principal Investigators                                    posures to the develop-
may not properly adhere to the cell
                                                Dr. Margaret Tucker and                                    ment of melanoma,”
matrix when cell division is com-
                                                Dr. Alisa Goldstein,                                       Dr. Tucker added.
plete, enabling them to subsequently
detach.                                         NCI’s Division of Cancer                                    Who Can Join
                                                Epidemiology and Genetics.                                  This Study?
Taken together, these two studies                                                                             Researchers seek to
provide a possible scenario of meta-            Why Is This Study Important?
                                                                                                              enroll members of 100
static initiation. Joint expression of          Melanoma is the fifth most
                                                                                                              families that may be
Rho and TrkB could cause some of                common cancer in men and
                                                                                  Dr. Margaret Tucker at high risk for devel-
the rapidly dividing cells in a tumor           the seventh most common           Principal Investigator      oping melanoma. To
to slough off and survive long enough            cancer in women. Each
                                                                                                              be eligible, the family
to find a new home. d                            year, more than 50,000 Americans
                                                                                            must have at least three living blood
                                                are diagnosed with skin melanoma
                                                                                            relatives ever diagnosed with invasive
                                                and more than 7,500 die from it. In
(Funding Opportunities continued from page 4)                                               melanoma. See the full list of eligibil-
                                                the last 30 years, the rate of newly
from other relevant disciplines with                                                        ity criteria for this study at http://can-
                                                diagnosed melanomas has more than
expertise in obesity and nutrition.                                                         cer.gov/clinicaltrials/NCI-02-C-0211.
                                                tripled in men and more than dou-
The goal is to increase the number                                                          Where Is This Study Taking Place?
                                                bled in women in the United States.
of useful technologies and tools avail-                                                     The study will be conducted at the
able to scientists to facilitate their re-      Researchers are studying members of
                                                                                            NIH Clinical Center in Bethesda, Md.
search in energy balance and health.            families in which there are multiple
                                                cases of melanoma to identify genes         Who to Contact
This PA uses the SBIR and STTR                                                              Contact the NCI Division of Cancer
                                                and precursor conditions that may
mechanisms, which are set-aside                                                             Epidemiology and Genetics, Genetic
                                                increase the likelihood of developing
programs.                                                                                   Epidemiology Branch referral nurse
                                                this disease.
For more information see http://cri.                                                        at 1-800-518-8474, or call the NCI
                                                “Studying this population has allowed
nci.nih.gov/4abst.cfm?initiativeparfa_                                                      Clinical Studies Support Center
                                                us to identify two major melanoma
id=2241. Inquiries: Dr. Sharon Ross,                                                        (CSSC) at 1-888-NCI-1937. The call
                                                susceptibility genes,” said Dr. Tucker.
sr75k@nih.gov; Dr. Connie Dresser,                                                          is toll free and confidential. d
                                                “We are now actively working with
cd34b@nih.gov; Dr. Audie A. Atienza,
                                                our colleagues in the International
atienzaa@mail.nih.gov d                                                                     An archive of “Featured Clinical Trial”
                                                Melanoma Genetics Consortium                columns is available at http://cancer.gov/
                                                to identify additional melanoma             clinicaltrials/ft-all-featured-trials.


6 NCI Cancer Bulletin
  Notes
Medicare Cancer Drug Benefit                demonstration and assist beneficia-          cluded the President’s Cancer Panel on
Enrollment Period Expanded                 ries in obtaining and completing the        August 30 at the first in a new series
The Centers for Medicare and Medicaid      application forms.                          of meetings on “Translating Research
Services (CMS) has announced that it                                                   to Reduce the Burden of Cancer.” The
                                           Scientific Presentations, Survivor
will the expand the enrollment period      Reflection Papers Available Online           meeting was hosted by the University
for the Medicare Replacement Drug          Highlights and slide presentations from     of California, San Francisco Cancer
Demonstration until 50,000 people are      the 2nd Biennial Cancer Survivorship        Center. Experts from government,
enrolled. Only 4,000 cancer patients       Research Conference: Pathways to            industry, and academia, as well as cli-
have signed up so far for Medicare         Health after Treatment, are now             nicians, third-party payers, and com-
coverage of their cancer drugs.            available on the NCI Office of Cancer         munity representatives, testified about
Medicare beneficiaries with cancer          Survivorship (OCS) Web site. The            barriers to developing rapidly emerg-
and other serious diseases who en-         June conference was cosponsored by          ing scientific discoveries into useful in-
rolled early in a new large-scale dem-     OCS and the American Cancer Society         terventions that can be delivered into
onstration program are now saving          (ACS). Leading researchers presented        the community. The role of academic
up to 90 percent on the cost of self-      findings on the most prevalent late ef-      medical centers in the discovery-de-
administrable drugs that replace drugs     fects related to cancer and its treatment   velopment-delivery continuum was
previously delivered only in physician     and on innovative interventions to re-      specifically explored.
offices, Dr. Mark B. McClellan, CMS          duce these effects on cancer survivors       The Panel will hold three additional
administrator, announced on Sept. 10.      and their families. National priorities     meetings on this topic, after which it
Beneficiaries with cancer, multiple         in cancer survivorship and data on the      will develop a report to the President
sclerosis, rheumatoid arthritis, and       projected economic burden of cancer         and Congress with recommendations.
other serious diseases who applied         survivorship were also presented.           For more information on this series of
by Aug. 16 began receiving benefits         A series of personal reflection papers       meetings, go to http://pcp.cancer.gov.
on Sept. 1. Those individuals who          written by cancer advocates who par-        Evans to Speak on Obesity and Cancer
enroll by Sept. 30 will begin receiving    ticipated in the Survivor-Researcher        On September 20 from 4-6 p.m.
benefits by Oct. 18.                        Mentor Program also can be found            in the Lipsett Amphitheater in the
The demonstration program is intended      on the OCS Web site. In collabora-          Clinical Center on the NIH campus,
to provide savings on certain drugs        tion with OCS and ACS, the Lance            Dr. Ronald M. Evans of the Gene
covered by Medicare Part B for ben-        Armstrong Foundation funded the             Expression Laboratory at the Salk
eficiaries without drug coverage. Until     mentor program to provide a forum           Institute in La Jolla, Calif., will
recently, patients were required to have   for research and advocacy communi-          present “Nuclear Receptors and the
these drugs administered by a physician.   ties to discuss the state of cancer sur-    Complex Journey to Obesity.” NIH
Under this demonstration program, “re-     vivorship science. All post-conference      Director Dr. Elias Zerhouni will make
placement” drugs are available for self-   materials are available at http://can-      opening remarks at this presentation,
administration, either orally or through   cercontrol.cancer.gov/ocs/pathways/.        which is part of the NCI/NIH Stars in
self-injection, which saves money and,     President’s Cancer Panel Holds              Nutrition & Cancer Seminar Series.
for many, is more convenient.              First of Four Meetings                      Dr. Evans will discuss the newest and
                                           The discovery engine through which          most significant problems arising
Information about the demonstra-
                                           scientists are gaining knowledge about      from obesity and how they relate to
tion, including brochures, application
                                           the biology and etiology of cancer is       cancer and explain how key regula-
forms, and a complete list of covered
                                           accelerating rapidly, but the speed         tors of energy balance may control
drugs, may be downloaded from the
                                           at which this knowledge is being            aspects of tumor growth.
CMS Web site at http://www.cms.
                                           transferred to clinicians, patients,        This free lecture is open to the public
hhs.gov/researchers/demos/drug-
                                           and communities lags behind. It is          and no registration is necessary.
coveragedemo.asp. Customer service
                                           critically important for the National       For more information go to: http://
representatives are available at 1-866-
                                           Cancer Program to focus on moving           www3.cancer.gov/prevention/nutri-
563-5386, or by TTY at 1-866-536-
                                           the results of research into practice in    tion/index.html. d
5387, to answer questions about the
                                           all communities of America. So con-
                                                                                                         7 NCI Cancer Bulletin
                    Featured Meetings

   This is a list of selected scientific meetings sponsored by NCI and other organizations. For locations and times
   and a more complete list of scientific meetings, including NCI’s weekly seminars and presentations open to the
   public, see the NCI Calendar of Scientific Meetings at http://calendar.cancer.gov.


   NCI Advisory Committee Upcoming Meetings
   Date        Advisory Committee
   Sept. 13-15     NCI Director’s Consumer Liaison Group
   Sept. 14-15     National Cancer Advisory Board
   Sept. 27        President’s Cancer Panel

   Selected Upcoming Meetings of Interest
   Date        Meeting                                                    NCI Speakers
   Sept. 13-14     First International Peritoneal                         Dr. Karen H. Antman, Deputy Director,
                   Mesothelioma Meeting                                   Translational and Clinical Sciences; Dr. Raffit
                                                                          Hassan, Deputy Director, Laboratory of Molecular
                                                                          Biology, Center for Cancer Research; Dr. H. Richard
                                                                          Alexander, Head, Surgical Metabolism Section,
                                                                          Surgery Branch, Center for Cancer Research

   Sept. 15        Patient Navigator Workshop                             Dr. Harold P. Freeman, Center to Reduce Cancer
                                                                          Health Disparities

   Sept. 17-19     Advances in the Multidisciplinary Treatment            Dr. James H. Doroshow, Director, Division of
                   of Gastrointestinal Neoplasms                          Cancer Treatment and Diagnosis

   Sept. 19-21     2004 Annual Convention & Community                     Dr. Harold P. Freeman, Center to Reduce Cancer
                   Health Institute                                       Health Disparities


   NCI Exhibits
   NCI Exhibits are presented at various professional and society meetings. Further information about
   the NCI Exhibits program can be found at http://exhibits.cancer.gov.




This NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI,            For more information on cancer,
which was established in 1937, leads a national effort to eliminate the suffering and          call 1-800-4-CANCER or visit
death due to cancer. Through basic and clinical biomedical research and training, NCI        http://cancer.gov.
conducts and supports research that will lead to a future in which we can prevent            NCI Cancer Bulletin staff can be reached
cancer before it starts, identify cancers that do develop at the earliest stage, eliminate   at ncicancerbulletin@mail.nih.gov.
cancers through innovative treatment interventions, and biologically control those
cancers that we cannot eliminate so they become manageable, chronic diseases.                NIH Publication No. 04-5498

8 NCI Cancer Bulletin

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:10
posted:11/3/2011
language:English
pages:8